"and intend to evaluate next steps for the LANI program outside of Japan with our partner, Daiichi Sankyo”.
Sounds good to me. We cut DS in on a RoW deal and receive royalties, while we get on with commercialising the Rhinovirus opportunity.
Alternatively - DS might find the whole of BTA tempting around today's prices.
Smashed, page-15
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)